Working Group 2

Pharmacogenetic Guideline Development and Optimization

wORKING GROUP 2

Pharmacogenetic Guideline Development and Optimization

Working Group 2 is dedicated to developing and optimizing pharmacogenomic guidelines for cardiovascular therapies. The group identifies clinical areas where genetic insights can significantly improve treatment outcomes and supports the transition toward personalized medicine.

Dr. Amela Jusić

Quant Biomarkers

By analyzing existing guidelines, genetic variants, and therapeutic approaches, WG2 works on creating structured, evidence-based recommendations for clinical use. A key focus is patient stratification, ensuring that treatment decisions are tailored based on genetic profiles, clinical conditions, and demographic factors.

This working group plays a critical role in translating research into practice, enabling clinicians to apply pharmacogenomic knowledge effectively and consistently across different healthcare systems.